Werewolf Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Core Insights - Werewolf Therapeutics is advancing its proprietary PREDATOR® platform, focusing on conditionally activated immune therapeutics for cancer treatment, with significant progress in its lead clinical programs WTX-124 and WTX-330, as well as the first INDUCER T-cell engager candidate, WTX-1011 [2][9] Clinical-Stage INDUKINE Molecules - WTX-124 has received Fast Track Designation from the FDA for treating locally advanced or metastatic cutaneous melanoma, with updates on clinical trial data and regulatory feedback expected in Q4 2025 [6][5] - WTX-330 is currently in a Phase 1b/2 clinical trial for advanced or metastatic solid tumors, with further development plans to be announced later in Q4 2025 [5][6] - WTX-1011 is undergoing IND-enabling studies, targeting STEAP1 for prostate cancer, with a differentiated target candidate expected to be nominated by year-end 2025 [11][5] Preclinical-Stage INDUCER Molecules - The company has development candidates available for partnering, including WTX-712 (IL-21), WTX-518 (IL-18), and WTX-921 (IL-10), aimed at treating various cancers and inflammatory diseases [7] Financial Results for Q3 2025 - Cash and cash equivalents as of September 30, 2025, were $65.7 million, down from $77.6 million as of June 30, 2025, expected to fund operations into Q4 2026 [12] - Research and development expenses were $11.6 million for Q3 2025, a decrease from $12.5 million in Q3 2024 [12] - General and administrative expenses were $4.1 million for Q3 2025, down from $4.6 million in Q3 2024 [12] - The net loss for Q3 2025 was $16.4 million, compared to a net loss of $16.7 million in Q3 2024 [12][15]